Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    NEXT STORY
    Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients
    PREV STORY
    Teleflex to Present at the 31st Annual Piper Jaffray Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019

    author_avatar
    NASDAQ Market News

    Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors

    ROCKVILLE, Md., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), ...

    author_avatar
    NASDAQ Market News

    electroCore Announces Distribution Agreement with Doctor’s Medical LLC to Expand Patient Access to gammaCore

    author_avatar
    NASDAQ Market News